Cancer research biotech ImmunSYS files for bankruptcy


    Fort Lauderdale-based biotechnology company ImmunSYS filed for Chapter 11 bankruptcy protection, noting that liquidity issues have prevented it from paying its debts as they come due.

    ImmunSYS, a clinical-stage biopharmaceutical company focused on developing cancer immunotherapy treatments, has nearly $10 million in liabilities and $330,720 in assets, according to a Dec. 31 bankruptcy petition filed in U.S. District Court for the Southern District of Florida. It has three employees.